Brokerages Anticipate Inspire Medical Systems (INSP) Will Announce Quarterly Sales of $13.20 Million

Wall Street analysts predict that Inspire Medical Systems (NASDAQ:INSP) will report sales of $13.20 million for the current fiscal quarter, Zacks reports. Three analysts have made estimates for Inspire Medical Systems’ earnings, with the highest sales estimate coming in at $14.10 million and the lowest estimate coming in at $11.60 million. The business is scheduled to announce its next quarterly earnings results on Tuesday, February 5th.

According to Zacks, analysts expect that Inspire Medical Systems will report full year sales of $48.00 million for the current year, with estimates ranging from $47.90 million to $48.10 million. For the next fiscal year, analysts expect that the firm will post sales of $61.80 million, with estimates ranging from $56.60 million to $64.50 million. Zacks’ sales averages are an average based on a survey of research firms that that provide coverage for Inspire Medical Systems.

Inspire Medical Systems (NASDAQ:INSP) last released its quarterly earnings data on Tuesday, November 6th. The company reported ($0.22) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.35) by $0.13. The business had revenue of $13.10 million during the quarter, compared to the consensus estimate of $12.86 million. The firm’s quarterly revenue was up 79.9% on a year-over-year basis. During the same period last year, the business posted ($3.42) earnings per share.

Several research analysts recently commented on INSP shares. Zacks Investment Research downgraded shares of Inspire Medical Systems from a “buy” rating to a “hold” rating in a report on Thursday, August 9th. Leerink Swann started coverage on shares of Inspire Medical Systems in a report on Monday, October 29th. They issued an “outperform” rating and a $57.00 price objective for the company. Three research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. The stock has an average rating of “Buy” and an average price target of $40.86.

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Alliancebernstein L.P. lifted its stake in Inspire Medical Systems by 57.3% in the 3rd quarter. Alliancebernstein L.P. now owns 11,800 shares of the company’s stock worth $497,000 after purchasing an additional 4,300 shares in the last quarter. Valeo Financial Advisors LLC purchased a new stake in Inspire Medical Systems in the 2nd quarter worth approximately $229,000. Wasatch Advisors Inc. lifted its stake in Inspire Medical Systems by 17.2% in the 3rd quarter. Wasatch Advisors Inc. now owns 35,006 shares of the company’s stock worth $1,473,000 after purchasing an additional 5,149 shares in the last quarter. Rhumbline Advisers purchased a new stake in Inspire Medical Systems in the 2nd quarter worth approximately $243,000. Finally, Dupont Capital Management Corp purchased a new stake in Inspire Medical Systems in the 3rd quarter worth approximately $314,000.

INSP opened at $46.39 on Friday. Inspire Medical Systems has a 12 month low of $22.50 and a 12 month high of $57.87.

Inspire Medical Systems Company Profile

Inspire Medical Systems, Inc, a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA). It offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea.

Read More: Ex-Dividend

Get a free copy of the Zacks research report on Inspire Medical Systems (INSP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Inspire Medical Systems (NASDAQ:INSP)

Receive News & Ratings for Inspire Medical Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inspire Medical Systems and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply